Study identifier:D0190C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses of AZD0328 in Patients with Schizophrenia
schizophrenia
Phase 2
No
AZD0328, Placebo
All
100
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD0328 low dose | - |
Experimental: 2 AZD0328 Optimal dose | - |
Experimental: 3 AZD0328 High dose | - |
Placebo Comparator: 4 Placebo Comparator | - |